Literature DB >> 27542654

Determination of recall rates for assessment in high-risk women undergoing annual surveillance breast MRI.

N A Healy1, S A O'Keeffe2.   

Abstract

AIM: To review all surveillance breast magnetic resonance imaging (MRI) examinations performed over a 6-year period at an Irish national centre to determine the recall rate, biopsy rate, and cancer-detection rates.
MATERIALS AND METHODS: All breast MRI examinations performed for surveillance purposes in women at high risk of developing breast cancer between January 2009 and December 2014 were reviewed. The Breast Imaging-Reporting and Data System (BI-RADS) score for each MRI examination was determined, the type of additional imaging performed, and the method of biopsy, if performed, was recorded. Histology of the biopsy specimens was reviewed.
RESULTS: Data for 715 women undergoing 1445 surveillance MRI examinations were identified. Of the examinations, 10.9% (157/1445) had MRI BI-RADS scores that required recall for further imaging and 6.3% (91/1445) required a biopsy. Recall rates were 14.2% (86/607) and 8.5% (71/838) in the prevalent and incident rounds, respectively. The overall cancer detection rate was 17 per 1000.
CONCLUSION: The current UK guideline was not achieved and no studies to date have achieved the target of <7%. Aiming for this target could risk lowering the cancer-detection rate. The authors would suggest a target rate of <15% and <10% for the prevalent round and incident rounds, respectively.
Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27542654     DOI: 10.1016/j.crad.2016.07.011

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  2 in total

1.  Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.

Authors:  Rodrigo Santa Cruz Guindalini; Yonglan Zheng; Hiroyuki Abe; Kristen Whitaker; Toshio F Yoshimatsu; Tom Walsh; David Schacht; Kirti Kulkarni; Deepa Sheth; Marion S Verp; Angela R Bradbury; Jane Churpek; Elias Obeid; Jeffrey Mueller; Galina Khramtsova; Fang Liu; Akila Raoul; Hongyuan Cao; Iris L Romero; Susan Hong; Robert Livingston; Nora Jaskowiak; Xiaoming Wang; Marcio Debiasi; Colin C Pritchard; Mary-Claire King; Gregory Karczmar; Gillian M Newstead; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Clin Cancer Res       Date:  2018-08-28       Impact factor: 12.531

2.  "High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis".

Authors:  Shay Shraga; Albert Grinshpun; Aviad Zick; Luna Kadouri; Yogev Cohen; Ofra Maimon; Yael Adler-Levy; Galina Zeltzer; Avital Granit; Bella Maly; Einat Carmon; Vardiella Meiner; Tamar Sella; Tamar Hamburger; Tamar Peretz
Journal:  Front Oncol       Date:  2021-09-02       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.